← Leaderboards
John James McNeil
Hennepin Healthcare Research Institute
$33,160,412
Attributed
$66,399,329
Total exposure
5
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $9.9M · FY2009–23$10M$7.5M$5M$2.5M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$100,905,003 · 6
By mechanism
U01$64,617,936 · 1
U19$34,662,686 · 4
R01$1,624,381 · 1
Top collaborators
- Anne M Murray12 shared
- Richard H Grimm10 shared
- Andrew T Chan8 shared
- Robyn Guymer5 shared
- Danny Liew3 shared
- Joanne Ryan3 shared
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseDisabilityRandomizedBenefits And RisksAspirinPharmaceutical PreparationsParticipantPrimary PreventionFollow-UpEventAustraliaElderlyLifeIncidenceAgedDoseAffectCessation Of LifeAging PopulationHemorrhageMalignant NeoplasmsCardiovascular SystemDementiaAge Group
Grant awards (27)
ConProject-006$34,776
U19 · FY2023 · AG
ConProject-005$19,131
U19 · FY2023 · AG
ASPirin in Reducing Events in the Elderly - eXTension$7,969,915
U19 · FY2022 · AG
ConProject-005$103,105
U19 · FY2022 · AG
ASPirin in Reducing Events in the Elderly - eXTension$8,509,004
U19 · FY2021 · AG
ASPirin in Reducing Events in the Elderly - eXTension$8,333,959
U19 · FY2020 · AG
Randomized controlled trial of the effect of low dose aspirin on the course of age-related macular degeneration$246,269
R01 · FY2020 · EY · contact PI
ASPirin in Reducing Events in the Elderly - eXTension$238,377
U19 · FY2020 · AG
ASPirin in Reducing Events in the Elderly - eXTension$9,454,419
U19 · FY2019 · AG
Randomized controlled trial of the effect of low dose aspirin on the course of age-related macular degeneration$350,790
R01 · FY2019 · EY · contact PI
ASPirin in Reducing Events in the Elderly$5,794,244
U01 · FY2018 · AG
Randomized controlled trial of the effect of low dose aspirin on the course of age-related macular degeneration$349,854
R01 · FY2018 · EY · contact PI
ASPirin in Reducing Events in the Elderly$4,941,881
U01 · FY2017 · AG
ASPirin in Reducing Events in the Elderly$936,324
U01 · FY2017 · AG
Randomized controlled trial of the effect of low dose aspirin on the course of age-related macular degeneration$348,949
R01 · FY2017 · EY · contact PI
ASPirin in Reducing Events in the Elderly$8,983,665
U01 · FY2016 · AG
Randomized controlled trial of the effect of low dose aspirin on the course of age-related macular degeneration$328,519
R01 · FY2016 · EY · contact PI
ASPirin in Reducing Events in the Elderly$122,144
U01 · FY2016 · AG
ASPirin in Reducing Events in the Elderly$8,485,338
U01 · FY2015 · AG
ASPirin in Reducing Events in the Elderly$702,600
U01 · FY2015 · AG
ASPirin in Reducing Events in the Elderly$8,233,724
U01 · FY2014 · AG
ASPirin in Reducing Events in the Elderly$276,000
U01 · FY2014 · AG
ASPirin in Reducing Events in the Elderly$8,542,640
U01 · FY2013 · AG
ASPirin in Reducing Events in the Elderly$1,352,658
U01 · FY2013 · AG
ASPirin in Reducing Events in the Elderly$936,165
U01 · FY2012 · AG
ASPirin in Reducing Events in the Elderly$9,375,981
U01 · FY2010 · AG
ASPirin in Reducing Events in the Elderly$5,934,572
U01 · FY2009 · AG